Vext Science (VEXTF) AI Stock Analysis

Vext Science

(Other OTC:VEXTF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Margin and EBITDA improvementImproving gross margins and adjusted EBITDA indicate stronger operating economics and better execution. If sustained, these gains can help Vext absorb fixed costs, narrow losses, generate more internal funding, and support investment in its higher-return markets over the next several quarters.

Negative Factors

Revenue decline and Arizona weaknessThe lower top line shows that operational improvement has not yet translated into broad revenue growth. Arizona wholesale contraction and cultivation wind-down reduce scale, while the Ohio ramp must offset that decline before Vext can establish a more consistently expanding revenue base.

Vext Science (VEXTF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $44.98M
Dividend Yield: ―
Average Volume (3M): 28.84K
Price to Earnings (P/E): -2.5
Beta (1Y): -0.06
Revenue Growth: 14.80%
EPS Growth: 10.52%
Country: US
Employees: 173
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Vext Science Business Overview & Revenue Model

Company Description

Vext Science, Inc., through its various subsidiaries, operates as a comprehensive agricultural technology, services, and property management company within the United States cannabis sector. Its operations span the entire product lifecycle, from cult...

Vext Science Earnings Call Summary

Earnings Call Date:Aug 19, 2026(Q2-2026)|% Change Since:-17.35%|Next Earnings Date:May 31, 2020

Earnings Call SentimentPositive

The call emphasized meaningful operational and margin improvements driven by Ohio execution and higher cultivation yields, alongside successful financing and balance sheet progress. These positives were balanced against a lower top line (driven by a planned Arizona cultivation wind-down), ongoing market weakness in Arizona, a significant uncertain tax liability, and modest reported operating cash flow due to deliberate inventory and payable timing. Management communicated a clear strategy to redeploy capital from Arizona to Ohio and to pay down debt, and they reported concrete near-term actions and improving trends.

Positive Updates

Improved Profitability and Margins

Gross profit rose to $6.7M from $4.9M a year ago and gross margin expanded to 55% (vs 36% prior year). Even before fair-value adjustments, margin improved to ~44% from ~39% year-over-year.

Negative Updates

Revenue Decline

Total revenue was $12.1M, down ~10% year-over-year; top-line decline driven primarily by a planned reduction in Arizona wholesale activity (wholesale revenue declined from $2.6M to $1.4M).

Company Guidance

Management guided to improved H2 performance as Arizona’s repositioning to a capital‑light retail/third‑party sourcing model completes, Ohio inventory converts to cash, Fairfield and the broader Ohio footprint scale, and capital is directed to strengthening the balance sheet, paying down debt, and funding Ohio growth; Q2 metrics cited as context include revenue of $12.1M (≈‑10% YoY, flat QoQ) with wholesale revenue down to $1.4M from $2.6M, gross profit $6.7M (vs $4.9M a year ago) and gross margin 55% (36% YoY; 44% before fair‑value adj.), adjusted EBITDA $3.4M (+22% QoQ from a corrected Q1 $2.8M) with a 28% adjusted EBITDA margin (vs 23%), net loss narrowed to $0.3M (vs $1.5M), cash from operations $1.2M (~10% cash‑flow margin) despite a deliberate $2M Ohio inventory build (expected to convert through H2; Ohio wholesale set a preliminary monthly record in July), cultivation yields now >100 g/plant (up ~68% over 2.5 years), Eloy property reclassified held‑for‑sale at $7.8M with proceeds earmarked to pay secured debt, cash ~$4.5M, net working capital improved from ‑$11.7M to ≈‑$0.9M (would be positive excluding an $11.7M uncertain tax position up from $8.1M), WPCU financing gross proceeds ≈$17M (used to refinance ~$10.5M WPCU debt, acquire Jackson, OH for $6M and fund expansion), and the East West Bank note maturity extended to Jan 2028.

Vext Science Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

VEXTF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSE:CWEB	53Neutral	CAD 84.10M	-1.06	-285.96%	―	-7.77%	-52.56%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:LABS	49Neutral	CAD 27.77M	-5.60	-13.79%	―	-6.74%	43.54%
TSE:LEEF	44Neutral	CAD 59.58M	-1.57	206.83%	―	―	―
TSE:AVCN	41Neutral	CAD 14.11M	-3.24	-108.44%	―	-0.23%	-142.54%
TSE:PLTH	40Underperform	CAD 35.21M	-0.39	-131.41%	―	-21.90%	-25.05%

* Healthcare Sector Average

Performance Comparison

VEXTF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
VEXTF	Vext Science	0.18	-0.02	-7.65%
TSE:LEEF	Leef Brands Inc	0.20	-0.10	-33.90%
TSE:CWEB	Charlotte's Web Holdings (OTC)	0.31	0.11	55.00%
TSE:LABS	Medipharm Labs (Otc)	0.07	-0.01	-13.33%
TSE:PLTH	Planet 13 Holdings, Inc.	0.10	-0.17	-61.82%
TSE:AVCN	Avicanna Inc	0.10	-0.16	-60.38%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Vext Science AI Stock Analysis